The Debate Between Electricity and Heat, Efficacy and Safety of Irreversible Electroporation and Radiofrequency Ablation in the Treatment of Liver Cancer: A Meta-analysis

Overview

Journal Open Life Sci

Specialty Biology

Date 2024 Dec 23

PMID 39711974

Authors

Rong Xing

Yutong Liu

Yang Liu

Haihong Jiang

Chao Liu

Jiru Du

Affiliations

Soon will be listed here.

Abstract

Both irreversible electroporation (IRE) and radiofrequency ablation (RFA) are viable ablation methods for localized treatment of liver tumors. We conducted a meta-analysis to access the efficacy and safety of IRE and RFA in liver cancer treatment. Clinical studies on IRE and RFA for the treatment of liver cancer were collected from PubMed and CNKI until June 2023. We screened the literature for ablation success rates at 1 month post-operation, extracting keywords such as "ablation success rate," "technical success rate," "recurrence rate," and "complication" for meta-analysis. A total of 37 articles were included: 24 related to RFA involving 1,685 cases and 13 related to IRE involving 524 cases. The results demonstrate that ablation success rates at post-operative 1 month for IRE and RFA were 86% (95% CI: 82-89%) and 87% (95% CI: 81-92%), respectively. Technical success rates were 96% (95% CI: 88-100%) and 99% (95% CI: 96-100%). In addition, the recurrence rate was 16% (95% CI: 12-22%) in RFA group and 16% (95% CI: 9-23%) in IRE group. In terms of safety, the RFA had a complication rate of 28% (95% CI: 10-50%) and the IRE had a rate of 26% (95% CI: 13-43%). In conclusion, IRE and RFA exhibit similar ablation success rates at 1 month post-operation and comparable complication rates, making them both safe and effective treatment options.

References

Niessen C, Thumann S, Beyer L, Pregler B, Kramer J, Lang S . Percutaneous Irreversible Electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors. Sci Rep. 2017; 7:43687. PMC: 5339813. DOI: 10.1038/srep43687. View

Poon R, Ng K, Lam C, Ai V, Yuen J, Fan S . Radiofrequency ablation for subcapsular hepatocellular carcinoma. Ann Surg Oncol. 2004; 11(3):281-9. DOI: 10.1245/aso.2004.08.018. View

Nieuwenhuizen S, Dijkstra M, Puijk R, Geboers B, Ruarus A, Schouten E . Microwave Ablation, Radiofrequency Ablation, Irreversible Electroporation, and Stereotactic Ablative Body Radiotherapy for Intermediate Size (3-5 cm) Unresectable Colorectal Liver Metastases: a Systematic Review and Meta-analysis. Curr Oncol Rep. 2022; 24(6):793-808. PMC: 9054902. DOI: 10.1007/s11912-022-01248-6. View

Mafeld S, Wong J, Kibriya N, Stenberg B, Manas D, Bassett P . Percutaneous Irreversible Electroporation (IRE) of Hepatic Malignancy: A Bi-institutional Analysis of Safety and Outcomes. Cardiovasc Intervent Radiol. 2018; 42(4):577-583. PMC: 6394503. DOI: 10.1007/s00270-018-2120-z. View

Charpentier K, Wolf F, Noble L, Winn B, Resnick M, Dupuy D . Irreversible electroporation of the liver and liver hilum in swine. HPB (Oxford). 2011; 13(3):168-73. PMC: 3048967. DOI: 10.1111/j.1477-2574.2010.00261.x. View

Schullian P, Johnston E, Putzer D, Eberle G, Laimer G, Bale R . Stereotactic radiofrequency ablation of subcardiac hepatocellular carcinoma: a case-control study. Int J Hyperthermia. 2019; 36(1):876-885. DOI: 10.1080/02656736.2019.1648886. View

Cheung W, Kavnoudias H, Roberts S, Szkandera B, Kemp W, Thomson K . Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience and review of safety and outcomes. Technol Cancer Res Treat. 2013; 12(3):233-41. DOI: 10.7785/tcrt.2012.500317. View

Thomson K, Cheung W, Ellis S, Federman D, Kavnoudias H, Loader-Oliver D . Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol. 2011; 22(5):611-21. DOI: 10.1016/j.jvir.2010.12.014. View

Gadaleta C, Catino A, Ranieri G, Fazio V, Gadaleta-Caldarola G, Cramarossa A . Single-step therapy -- feasibility and safety of simultaneous transarterial chemoembolization and radiofrequency ablation for hepatic malignancies. In Vivo. 2009; 23(5):813-20. View

10.

Ahmed M, Brace C, Lee Jr F, Goldberg S . Principles of and advances in percutaneous ablation. Radiology. 2011; 258(2):351-69. PMC: 6939957. DOI: 10.1148/radiol.10081634. View

11.

Giorgio A, Di Sarno A, de Stefano G, Farella N, Scognamiglio U, de Stefano M . Hepatocellular carcinoma with cirrhosis: are patients with neoplastic main portal vein invasion eligible for percutaneous radiofrequency ablation of both the nodule and the portal venous tumor thrombus?. AJR Am J Roentgenol. 2009; 193(4):948-54. DOI: 10.2214/AJR.08.2087. View

12.

Freeman E, Cheung W, Kavnoudias H, Majeed A, Kemp W, Roberts S . Irreversible Electroporation For Hepatocellular Carcinoma: Longer-Term Outcomes At A Single Centre. Cardiovasc Intervent Radiol. 2020; 44(2):247-253. DOI: 10.1007/s00270-020-02666-4. View

13.

Sutter O, Calvo J, Nkontchou G, Nault J, Ourabia R, Nahon P . Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series. Radiology. 2017; 284(3):877-886. DOI: 10.1148/radiol.2017161413. View

14.

Scheffer H, Nielsen K, de Jong M, van Tilborg A, Vieveen J, Bouwman A . Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol. 2014; 25(7):997-1011. DOI: 10.1016/j.jvir.2014.01.028. View

15.

Eisele R, Chopra S, Glanemann M, Gebauer B . Risk of local failure after ultrasound guided irreversible electroporation of malignant liver tumors. Interv Med Appl Sci. 2015; 6(4):147-53. PMC: 4274353. DOI: 10.1556/IMAS.6.2014.4.2. View

16.

Orlacchio A, Chegai F, Del Giudice C, Massaccesi M, Costanzo E, Di Caprera E . Radiofrequency thermoablation of HCC larger than 3 cm and less than 5 cm proximal to the gallbladder without gallbladder isolation: a single center experience. Biomed Res Int. 2014; 2014:896527. PMC: 4163369. DOI: 10.1155/2014/896527. View

17.

Zhang X, Zhang X, Ding X, Wang Z, Fan Y, Chen G . Novel irreversible electroporation ablation (Nano-knife) versus radiofrequency ablation for the treatment of solid liver tumors: a comparative, randomized, multicenter clinical study. Front Oncol. 2022; 12:945123. PMC: 9557230. DOI: 10.3389/fonc.2022.945123. View

18.

Komorizono Y, Oketani M, Sako K, Yamasaki N, Shibatou T, Maeda M . Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. Cancer. 2003; 97(5):1253-62. DOI: 10.1002/cncr.11168. View

19.

Hou Y, Chen M, Yan K, Wu J, Yang W . Adjuvant percutaneous radiofrequency ablation of feeding artery of hepatocellular carcinoma before treatment. World J Gastroenterol. 2009; 15(21):2638-43. PMC: 2691496. DOI: 10.3748/wjg.15.2638. View

20.

Edd J, Horowitz L, Davalos R, Mir L, Rubinsky B . In vivo results of a new focal tissue ablation technique: irreversible electroporation. IEEE Trans Biomed Eng. 2006; 53(7):1409-15. DOI: 10.1109/TBME.2006.873745. View